Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1053/j.seminoncol.2008.01.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vincamine, from an antioxidant and a cerebral vasodilator to its anticancer potential.
Bioorg Med Chem
September 2023
Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210, United States. Electronic address:
Vincamine is a naturally occurring indole alkaloid showing antioxidant activity and has been used clinically for the prevention and treatment of cerebrovascular disorders and insufficiencies. It has been well documented that antioxidants may contribute to cancer treatment, and thus, vincamine has been investigated recently for its potential antitumor activity. Vincamine was found to show cancer cell cytotoxicity and to modulate several important proteins involved in tumor growth, including acetylcholinesterase (AChE), mitogen-activated protein kinase (MAPK), nuclear factor-κB (NF-κB), nuclear factor erythroid 2-related factor 2 (Nrf2), and T-box 3 (TBX3).
View Article and Find Full Text PDFVinca alkaloids as a potential cancer therapeutics: recent update and future challenges.
3 Biotech
June 2023
Department of Biotechnology, Faculty of Applied Sciences and Biotechnology, Shoolini University of Biotechnology and Management Sciences, Solan, Himachal Pradesh 173229 India.
Vinca alkaloids including vincristine, vinblastine, vindesine, and vinflunine are chemotherapeutic compounds commonly used to treat various cancers. Vinca alkaloids are one of the first microtubule-targeting agents to be produced and certified for the treatment of hematological and lymphatic neoplasms. Microtubule targeting agents like vincristine and vinblastine work by disrupting microtubule dynamics, causing mitotic arrest and cell death.
View Article and Find Full Text PDFEpithelial-to-Mesenchymal Transition Mediates Resistance to Maintenance Therapy with Vinflunine in Advanced Urothelial Cell Carcinoma.
Cancers (Basel)
December 2021
Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA.
In the phase II MAJA trial, maintenance therapy with vinflunine resulted in longer progression-free survival compared to best supportive care in advanced urothelial cell carcinoma (aUCC) patients who did not progress after first-line platinum-based chemotherapy. However, despite an initial benefit observed in some patients, unequivocal resistance appears which underlying mechanisms are presently unknown. We have performed gene expression and functional enrichment analyses to shed light on the discovery of these underlying resistance mechanisms.
View Article and Find Full Text PDFVinca alkaloids and analogues as anti-cancer agents: Looking back, peering ahead.
Bioorg Med Chem Lett
September 2018
Department of Drug Sciences, Medicinal Chemistry Section, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. Electronic address:
Cancer still represents a "nightmare" worldwide, causing annually millions of victims. Several antiproliferative molecules are currently used as drugs market and offer a pharmaceutical opportunity for attenuating and treating tumor manifestations. In this context, natural sources have a relevant role, since they provide the 60% of currently-used anticancer agents.
View Article and Find Full Text PDFEribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
Cancer Treat Rev
April 2012
Department of Oncology, Vall d´Hebron University Hospital, Barcelona, Spain.
Background: Microtubule-targeted agents are one of the most common classes of chemotherapeutic drug for the treatment of breast cancer. Limitations of current microtubule-targeted agents such as primary or secondary resistance of cancer cells and side effects like neuropathy prompted the discovery and introduction of newer more effective drugs. This review aims to provide a summary of the novel halichondrin B analog eribulin mesylate (E7389) and illustrate where it is placed in the treatment arena versus other agents that are approved or are currently in various stages of clinical development.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!